<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682210</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-280-01</org_study_id>
    <nct_id>NCT04682210</nct_id>
  </id_info>
  <brief_title>Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection</brief_title>
  <acronym>DaDaLi</acronym>
  <official_title>A Phase III, Randomized, Open-lable, Multi Center Study of Sintilimab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Curative Hepatic Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, randomized, controlled phase III study, to evaluate the&#xD;
      efficacy and safety of sintilimab plus bevacizumab as adjuvant therapy in hepatocellular&#xD;
      carcinoma (HCC) patients who are at high risk of recurrence after radical resection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no stardard adjuvant treatment for HCC. This study is to to evaluate the efficacy&#xD;
      and safety of sintilimab plus bevacizumab as adjuvant therapy in HCC patients who are at high&#xD;
      risk of recurrence after radical resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free Survival (RFS)</measure>
    <time_frame>up to 36 months after randomization</time_frame>
    <description>RFS is defined as the time from randomization to the first documented occurrence of local, regional, or metastatic HCC as determined by the investigator, or death due to any cause (whichever occurs first).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS）</measure>
    <time_frame>up to 48 months after randomization</time_frame>
    <description>OS is defined as the time from the date of randomisation until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS Rate at 12 and 24 months</measure>
    <time_frame>at 12 and 24 months after randomization</time_frame>
    <description>RFS rate defined as the proportion of patients without recurrence or death from any cause at 12 and 24 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate at 24 and 36 Months</measure>
    <time_frame>at 24 and 36 months after randomization</time_frame>
    <description>OS rate defined as the proportion of patients who have not experienced death from any cause at 24 and 36 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR(time to recurrence)</measure>
    <time_frame>up to 36 months after randomization</time_frame>
    <description>TTR is defined as the time the date of randomisation until first documented disease recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>up to 48 months after randomization</time_frame>
    <description>The grade of AEs and the number of patients with AEs are assessed by the investigator based on CTCAE v5.0 from the date of randomization to 90 days after last dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">246</enrollment>
  <condition>HCC</condition>
  <condition>Adjuvant Therapy</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sintilimab 200mg + bevacizumab 7.5mg/kg IV Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Active surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab 200mg IV Q3W</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Tyvyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 7.5mg/kg IV Q3W</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Byvasda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a first diagnosis of HCC who have undergone a curative resection&#xD;
&#xD;
          -  Radiologic evidence of disease free ≥4 weeks after complete surgical resection&#xD;
&#xD;
          -  Full recovery from surgical resection or post-operative transarterial&#xD;
             chemoembolization before randomization&#xD;
&#xD;
          -  Randomization needs to occur within 12 weeks of the date of surgical resection&#xD;
&#xD;
          -  High risk for HCC recurrence as protocol defined&#xD;
&#xD;
          -  Child-Pugh Score, Class A&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  No prior systemic anticancer therapy for HCC&#xD;
&#xD;
          -  Adequate hematologic and organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC&#xD;
&#xD;
          -  Evidence of residual, recurrent, or metastatic disease at randomization&#xD;
&#xD;
          -  History of hepatic encephalopathy or organ transplantation&#xD;
&#xD;
          -  Patients who are in the waiting list for liver transplantation&#xD;
&#xD;
          -  Patients with Vp4 portal vein thrombosis&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other&#xD;
             immunotherapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhongguo Zhou</last_name>
    <phone>020-87343585</phone>
    <email>54757370@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Chen Min-Shan</investigator_full_name>
    <investigator_title>MD, Department of Hepatobilliary Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

